Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

NAV Update

1 Apr 2022 11:05

NAV Update

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

1 April 2022

Net asset value (“NAV”) update for the period ended 31 March 2022

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios as at 31 March 2022.

Ordinary Shares

As at 31 March 2022, the unaudited NAV of an Ordinary share was 29.0p per share.

This is a decrease of 0.2p from the previously published unaudited NAV as at 23 March 2022 of 29.2p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc offset by an increase in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2022, shares in Scancell Holdings Plc were valued at 10.5p per share (23 March 2022: 11.5p) and shares in Arecor Therapeutics Plc were valued at 390p per share (23 March 2022: 350p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

No further investments or disposals have been made by the Ordinary share pool in the period since 24 March 2022 being the date up to which the post balance sheet events disclosure in the 31 December 2021 Annual Report related.

B Shares

As at 31 March 2022, the unaudited NAV of a B share was 96.7p per share.

This is a decrease of 3.4p from the previously published audited NAV as at 31 December 2021 of 100.1p and is due to changes in the value of the B share pool’s AIM quoted investments combined with the impact of running costs incurred in the period offset by profits realised from the sale of shares in some of the B share pool’s AIM quoted investments. The Directors also reviewed the unquoted investments held in the B share portfolio and concluded that no changes were required to the carrying value of those investments.

The B share pool made three additional investments in the quarter ending 31 March 2022:

£500k into the AIM IPO of Clean Power Hydrogen Plc, which has now been fully exited. £280k into AIM quoted Verici Dx Plc.£530k into AIM quoted Celadon Pharmaceuticals Plc.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2022 and unquoted investments are carried at fair value as at 31 March 2022.

The number of B shares in issue at 31 March 2022 was 14,588,659 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 22,704,035.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

The Offer by the Company remains open for the 2021/22 tax year until midday on 4 April 2022.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
28th Apr 202110:52 amGNWIssue of Equity and Total Voting Rights
1st Apr 20215:29 pmGNWDirector/PDMR Shareholding
1st Apr 202111:36 amGNWIssue of Equity and TVR
31st Mar 20217:00 amGNWNet Asset Value(s)
29th Mar 20215:12 pmGNWResult of AGM
4th Mar 20215:26 pmGNWDirector/PDMR Shareholding
2nd Mar 202112:50 pmGNWIssue of Equity and Total Voting Rights
24th Feb 20211:49 pmGNWIssue of Prospectus
23rd Feb 20217:00 amGNWFinal Results and NAV Update
18th Feb 20217:00 amGNWDividend Declaration
10th Dec 20203:57 pmGNWDirector/PDMR Shareholding
9th Dec 20203:49 pmGNWIssue of Equity and Total Voting Rights
5th Nov 20207:00 amGNWDividend Declaration
13th Oct 20204:22 pmGNWOffer for Subscription
5th Oct 20207:00 amGNWSecond Interim Capital Dividend
5th Oct 20207:00 amGNWNAV Update
16th Sep 20207:00 amGNWInvestment Realisations and NAV
21st Aug 202010:55 amGNWChange of Registered Office
30th Jul 20207:00 amGNWHalf-year report
10th Jul 202011:43 amGNWIssue of Equity
24th Jun 202012:35 pmGNWB Share - Extension of Offer
13th May 20203:03 pmGNWPublication of a supplementary prospectus
29th Apr 202012:45 pmGNWIssue of Equity
29th Apr 20207:00 amGNWResult of Annual General Meeting
27th Apr 20206:52 pmGNWUpdate on Omega, Optibiotix and NAVs
20th Apr 20206:36 pmGNWOmega Diagnostics, Net Asset Value, New B Share Pool Investments
7th Apr 20204:35 pmGNWIssue of Supplementary Prospectus
3rd Apr 20202:10 pmGNWIssue of Equity
31st Mar 20205:30 pmGNWNet Asset Value(s)
26th Mar 20204:31 pmGNWAGM Venue Change
13th Mar 20204:14 pmGNWInterim Dividend
10th Mar 20202:28 pmGNWIssue of Equity
10th Mar 20207:00 amGNWB Share Net Asset Value
3rd Mar 20204:30 pmGNWIssue of Supplementary Prospectus
27th Feb 20207:00 amGNWFinal Results
9th Dec 20195:45 pmGNWDirectorate Change
27th Nov 20192:45 pmGNWIssue of Equity
20th Nov 20194:00 pmGNWDuplicate: Second Interim Dividend
28th Oct 20197:00 amGNWSecond interim dividend
10th Oct 20196:30 pmGNWDirector/PDMR Shareholding
10th Jun 20196:14 pmRNSResult of AGM
16th May 20197:00 amRNSSecond Interim Dividend
29th Apr 20198:52 amRNSFinal Results
25th Apr 20197:00 amRNSNet Asset Value(s)
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.